A benign condition that may develop into a cancer such as multiple myeloma
MGUS is defined by the following 3 criteria:
A serum monoclonal protein <30 g/L
Clonal bone marrow plasma cells <10%
Absence of end organ damage that can be attributed to the plasma cell proliferative disorder
Annually, around 1% of people with MGUS go on to develop Multiple Myeloma (MM) or a related malignancy.
International Guidelines recommend MGUS patients should be risk stratified at diagnosis to optimise counselling and follow-up.
In combination with other laboratory tests, Freelite serum free light chain (FLC) assay identifies patients at low risk of progression (~40%). This saves time, money and patient discomfort, as fewer clinic visits and tests are needed.
